Northern California Scleroderma Research Consortium
Location(s): United States
The Stanford group continues to collaborate with researchers at University of California San Francisco to further develop the Northern California Scleroderma Research Consortium (NCSRC). This partnership further develops and enhances a multi-center, multidisciplinary scleroderma cohort, database and tissue repository that can be used to address basic and translational questions relating to the biology and clinical outcomes of patients with scleroderma, related lung disease and other affiliated symptoms. By combining the clinical and research strengths of multiple Scleroderma Centers, the cohort will be large enough for meaningful comparison of the natural history and survival of various subsets of scleroderma patients.
The Stanford Scleroderma Center has grown substantially over the past four years, with more than 500 scleroderma patients evaluated and treated annually. The Center also actively carries out state-of-the-art research using tissue samples from scleroderma patients and works with a team of scientists to better understand what causes scleroderma. In addition, Stanford researchers are working to find markers in the skin or blood that can tell which patients will respond best to which therapies. The Center has recently found markers in skin biopsies that might determine if patients will experience softening of the skin with medications like imatinib or abatacept.